Target |
Mechanism ERs modulators |
Originator Org. |
Active Indication |
Inactive Indication |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc. JP |
First Approval Date31 Mar 1995 |
Target |
Mechanism AR agonists |
Active Org. |
Originator Org. |
Inactive Indication |
Drug Highest PhasePhase 2 |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target |
Mechanism AR modulators |
Active Org.- |
Originator Org. |
Active Indication- |
Inactive Indication |
Drug Highest PhaseDiscontinued |
First Approval Ctry. / Loc.- |
First Approval Date- |
Start Date28 Jun 2018 |
Sponsor / Collaborator |
Start Date28 May 2018 |
Sponsor / Collaborator |
Start Date21 Aug 2017 |
Sponsor / Collaborator |
Drug(Targets) | Indications | Global Highest Phase |
---|---|---|
Andarine ( AR ) | Cachexia More | Discontinued |
Enobosarm ( AR ) | Triple Negative Breast Cancer More | Discontinued |
MK-3984 ( AR ) | Sarcopenia More | Discontinued |
GTx-758 ( ERα ) | Prostatic Cancer More | Discontinued |
GTx-027 ( AR ) | Breast Cancer More | Pending |